Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 16/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23059281 | 1.00 | PDE8B (0.40) | PDE8BKDM4EKMT2APDE10APDE2A | |
| SCHEMBL23059284 | 0.86 | PDE8B (0.41) | PDE8BKDM4EKMT2APDE10APSMD14 | |
| SCHEMBL23059283 | 0.79 | ADORA2A (0.33) | KDM4EPDE2A | |
| SCHEMBL23059275 | 0.79 | ADORA2A (0.33) | KDM4EPDE2A | |
| SCHEMBL23059277 | 0.79 | ADORA2A (0.33) | KDM4EPDE2A | |
| SCHEMBL23059288 | 0.77 | PDE8B (0.45) | PDE8B | |
| SCHEMBL23059276 | 0.75 | — | — | |
| SCHEMBL23059280 | 0.73 | KMT2A (0.46) | KDM4EKMT2A | |
| SCHEMBL23059282 | 0.72 | PI4KB (0.54) | KDM4EKMT2A | |
| SCHEMBL15627374 | 0.72 | PI4KB (0.54) | KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | PDE8B 645/4885KDM4E 2229/4885KMT2A 2628/4885 |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PDE8B 1354/4885KDM4E 1756/4885KMT2A 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.